Abstract: Method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering an androgen, such as dehydroepiandrosterone or testosterone, to the female for at least about one month, and then evaluating a second anti-Müllerian hormone level of the female. Change in the anti-Müllerian hormone level is indicative of change in the ovarian reserve, e.g., when the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level, the ovarian reserve has improved. The androgen administration may continue until the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level by a desired percentage or amount.

Abstract: Method of using an androgen, such as dehydroepiandrosterone (DHEA) or testosterone, to improve human folliculogenesis. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of the androgen per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of an androgen per day to the female for at least four months.

Abstract: A method of treating a human female with an androgen and a gonadotropin to improve at least one of the human female's infertility, reproductive outcomes and oocyte yield is disclosed. The method may include treating the female with an androgen and a gonadotropin in combination. The androgen may be administered for more than six weeks and the gonadotropin may be administered in a regular low dosage over a period of time longer than two weeks. The method may include inducing ovulation in the female by administering gonadotropins to stimulate ovulation and/or induce ovulation. The method may include multiple additional inductions of ovulation, each within 120 days of the previous induction of ovulation.

Abstract: Method of using an androgen, such as dehydroepiandrosterone (DHEA) or testosterone, to improve human folliculogenesis. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of the androgen per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of an androgen per day to the female for at least four months.

Abstract: Method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering an androgen, such as dehydroepiandrosterone or testosterone, to the female for at least about one month, and then evaluating a second anti-Müllerian hormone level of the female. Change in the anti-Müllerian hormone level is indicative of change in the ovarian reserve, e.g., when the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level, the ovarian reserve has improved. The androgen administration may continue until the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level by a desired percentage or amount.

Abstract: The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.

Abstract: The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.

Abstract: A method of improving cumulative embryo score may comprise administering an androgen to a human female for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. A method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. A method of normalizing ovarian DHEA may include administering an androgen for at least about four consecutive months. A method of decreasing the time to pregnancy and increasing the rate of pregnancy by administering an androgen for at least about two months. A method of decreasing miscarriage rates may comprise administering an androgen for at least about two months to a female. Moreover, a method of decreasing aneuploidy rates in human embryos may comprise administering an androgen to a female for at least about two months.

Abstract: The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.

Abstract: The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.

Abstract: A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a human female per day. Moreover, a method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. Furthermore, a method of increasing the quantity of day 3 embryos from one cycle of in vitro fertilization may comprise administering an androgen for at least about four consecutive months, harvesting and fertilizing the oocytes and forming day 3 embryos. A method of normalizing ovarian DHEA also may include administering an androgen for at least about four consecutive months.